Med BioGene - Welcome to Med BioGene

Featured News

November 28, 2008

Med BioGene Reports Financial Results for the Third Quarter 2008

October 23, 2008

Med BioGene Broadens Commercialization Team to Oversee Launch Preparations for LungExpress Dx™ Gene Expression Test

September 18, 2008

Med BIoGene Completes Final Tranche of Financing

Home

Welcome to Med BioGene

Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and screening tests for cancer and cardiovascular disease.

MBI’s lead products are LungExpress Dx™, a gene expression-based prognostic test for lung cancer, and LymphExpress Dx™, a gene expression-based diagnostic and prognostic test for lymphoma.

A Message From Our CEO

Med BioGene Completes Final Tranche of Financing

E-MAIL ALERTS

Subscribe to our e-mail news alerts

Quick Facts

Download our facts sheet